MétaCan
Menu
Back to cohort
Record W2769087419 · doi:10.1016/j.bbmt.2017.12.368

Safety of Two-Hour Intermittent Intravenous Infusions of Tacrolimus in the Allogeneic Hematopoietic Stem Cell Transplantation Unit

2018· article· en· W2769087419 on OpenAlexaff
Alexander JS Bacopoulos, Lina Ho, Anjie Yang, Pamela Ng, Celina Dara, David Loach, Uday Deotare, Fotios V. Michelis, Auro Viswabandya, Dennis Dong Hwan Kim, Jeffrey H. Lipton, Hans A. Messner, Santhosh Thyagu

Bibliographic record

VenueBiology of Blood and Marrow Transplantation · 2018
Typearticle
Languageen
FieldMedicine
TopicNeurological Complications and Syndromes
Canadian institutionsUniversity of TorontoUniversity Health Network
Fundersnot available
KeywordsMedicineTacrolimusNephrotoxicityTransplantationClinical endpointPopulationHematopoietic stem cell transplantationIncidence (geometry)SurgeryInternal medicineToxicityClinical trial

Abstract

fetched live from OpenAlex

Background: Administering intravenous (IV) tacrolimus by 24-hour continuous IV infusion (CIV), as recommended by the product monograph, poses significant logistical challenges in the allogeneic hematopoietic stem cell transplantation (alloHSCT) unit because it requires a dedicated central venous catheter lumen. Consequently, at our institution, tacrolimus has been administered via two-hour intermittent IV infusions (IIV) every twelve hours in the alloHSCT unit. Administration by IIV is not the standard of practice and shorter infusion times are cautioned due to higher rates of nephrotoxicity, neurotoxicity and infusion-related reactions (IRRs), although there is a paucity of data to support these claims. The primary objective of this retrospective study was to evaluate the safety of a two-hour IIV of tacrolimus in an adult alloHSCT population. Efficacy was evaluated as a secondary endpoint. Methods and patients: We performed a retrospective chart review of all patients who received IV tacrolimus at our institution from January 2002-January 2016. We reviewed 104 patients who received 118 treatment courses of tacrolimus by IIV (TCTIV) (median number of doses per TCTIV = 22, range 1-158). Primary outcomes collected include rates of nephrotoxicity, neurotoxicity and IRRs that occurred during TCTIV. The incidence of acute graft-versus-host disease (aGVHD) and disease relapse within 180 days of transplant were collected to evaluate efficacy. Results and discussion: There were sixteen incidences (13.6%) of nephrotoxicity, defined as a doubling of serum creatinine from baseline. Nephrotoxicity resolved in all but six (5.1%) cases. Precipitating factors for nephrotoxicity unrelated to tacrolimus were identified by the physician in all six cases. There were 41 incidences (34.7%) of neurotoxicity [seizure, posterior reversible encephalopathy syndrome (PRES), tremor, paresthesia, visual disturbance], of which, eight (6.8%) were considered serious (seizure and/or PRES). All neurotoxicity reverted to baseline or resolved completely. One (.1%) grade 2 infusion reaction occurred and resolved without discontinuation of tacrolimus. In the subset of patients who received tacrolimus for the prevention of aGVHD (n = 43), fifteen patients (34.9%) developed grade II-IV aGVHD. Nine patients (8.7%) experienced relapse of their disease. Conclusions: We propose that a two-hour IIV of tacrolimus is a safe method of administration in an adult alloHSCT setting. Additional safety and efficacy data from other institutions will provide external validity to this conclusion.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.678
Threshold uncertainty score0.255

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.021
GPT teacher head0.268
Teacher spread0.247 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueBiology of Blood and Marrow TransplantationSame topicNeurological Complications and SyndromesFrench-language works237,207